Retrospective Clinical Study Management for Active Medical Device in Pancreatic Tumor Ablation

1. Background and project objectives

A manufacturer of a Class II (US) and Class IIb (EU) active medical device cleared via 510(k) for soft tissue ablation sought to evaluate real-world surgeon utilization of the device for pancreatic tumor ablation. Although existing retrospective clinical data had been collected and analyzed, the manufacturer preferred a structured approach using a prospective study protocol and case report forms. The objectives included obtaining Institutional Review Board (IRB) approval, ensuring full compliance with HIPAA regulations, and generating high-quality data suitable for potential future FDA submissions. The study focused on assessing device safety as the primary endpoint and patient outcomes as the secondary endpoint.

2. Key challenges in study execution

Retrospective data collection presented multiple complexities, including identifying available source data across clinical sites and assessing the quality and usability of radiographic imaging (MRI/CT). Ensuring an unbiased evaluation required independent third-party involvement for all data collection and analysis. Coordination with multiple stakeholders was essential to maintain scientific integrity while meeting tight timelines. The need to involve specialized oncological surgeons for the Data Safety Monitoring Board (DSMB) and an independent radiologist added layers of logistical and regulatory requirements.

3. Project team assembly and preparation

A dedicated project team was formed consisting of a Senior Clinical Consultant, a Senior Regulatory Consultant, and a Clinical Monitor. Three experienced surgical oncologists were interviewed, selected, and trained to serve on the DSMB. An independent radiologist was engaged specifically to perform critical reviews of all MRI and CT imaging. All study-related documentation, including the protocol and supporting materials, was developed and placed under formal document control to ensure traceability and compliance.

4. IRB submission and contract management

Two highly regarded clinical sites were selected and supported through the IRB submission process. Contracts with both sites were negotiated and executed. Both IRBs granted approval within 45 days of submission, demonstrating efficient preparation and strong site relationships. This rapid timeline enabled swift progression to data collection activities.

5. Data collection, management, and analysis

Data were collected from 21 patients diagnosed with Stage III pancreatic cancer. Collected elements included patient demographics, baseline and follow-up blood chemistry results, imaging studies, adverse events (coded using MedDRA), and clinical scores/outcomes. All data collection, coding, and database freeze were completed within 30 days of study initiation. The independent radiologist reviewed relevant imaging source data, and the DSMB conducted its review, with both processes finalized within 30 days of the database freeze. Statistical analysis was performed, and the final clinical study report was drafted and completed within an additional 30 days.

6. Efficiency measures and compliance safeguards

The project leveraged extensive prior experience in designing, implementing, and managing more than 20 Phase II and Phase III clinical studies across the US and EU. A network of Field Monitors was utilized to streamline data collection and accelerate timelines. All activities strictly adhered to HIPAA requirements and maintained independence to ensure unbiased results. The combination of prospective protocol elements with retrospective data sources created a robust hybrid study design that maximized data quality while minimizing patient burden.

7. Outcomes and long-term value

The study delivered an independent, unbiased confirmation of the device’s safety profile when used for pancreatic soft tissue tumor ablation. Results demonstrated that the device could be safely applied in the selected patient population and provided a strong foundation for initiating a prospective Phase II clinical study. The entire project was completed within a six-to-seven-month timeframe. The resulting dataset and clinical report offer significant value for future regulatory submissions, supporting ongoing product development, labeling expansions, and evidence-based marketing efforts while reinforcing the manufacturer’s commitment to clinical excellence and patient safety.